New shot aims to save sight in dry macular degeneration
NCT ID NCT06990269
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 41 times
Summary
This study tests an investigational drug called ADX-038 in 240 people with geographic atrophy, an advanced form of dry age-related macular degeneration that causes blind spots. The drug is given as a shot under the skin and is compared to a placebo to see if it can slow the loss of a key layer in the retina over 12 months. Participants must have a certain size of retinal damage and be willing to receive required vaccinations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
ADARx Clinical Site
RECRUITINGGilbert, Arizona, 85297, United States
-
ADARx Clinical Site
RECRUITINGPhoenix, Arizona, 85020, United States
-
ADARx Clinical Site
RECRUITINGBeverly Hills, California, 90211, United States
-
ADARx Clinical Site
RECRUITINGHuntington Beach, California, 93647, United States
-
ADARx Clinical Site
RECRUITINGPoway, California, 92064, United States
-
ADARx Clinical Site
RECRUITINGOrlando, Florida, 32806, United States
-
ADARx Clinical Site
RECRUITINGWildwood, Florida, 34785, United States
-
ADARx Clinical Site
RECRUITINGHagerstown, Maryland, 21740, United States
-
ADARx Clinical Site
RECRUITINGReno, Nevada, 89502, United States
-
ADARx Clinical Site
RECRUITINGErie, Pennsylvania, 16505, United States
-
ADARx Clinical Site
RECRUITINGAustin, Texas, 78705, United States
-
ADARx Clinical Site
RECRUITINGDallas, Texas, 75231, United States
-
ADARx Clinical Site
RECRUITINGMcAllen, Texas, 78503, United States
-
ADARx Clinical Site
RECRUITINGRound Rock, Texas, 78681, United States
-
ADARx Clinical Site
RECRUITINGSan Antonio, Texas, 78340, United States
-
ADARx Clinical Site
RECRUITINGThe Woodlands, Texas, 77384, United States
-
ADARx Clinical Site
RECRUITINGSt. George, Utah, 84790, United States
-
ADARx Clinical Site
RECRUITINGAlbury, New South Wales, 2640, Australia
-
ADARx Clinical Site
RECRUITINGHurstville, New South Wales, 2220, Australia
-
ADARx Clinical Site
RECRUITINGParramatta, New South Wales, 2150, Australia
-
ADARx Clinical Site
RECRUITINGEast Melbourne, Victoria, 3002, Australia
-
ADARx Clinical Site
RECRUITINGRowville, Victoria, 3178, Australia
-
ADARx Clinical Site
RECRUITINGOttawa, Ontario, K2B 7E9, Canada
-
ADARx Clinical Site
RECRUITINGToronto, Ontario, M8X 2X3, Canada
Conditions
Explore the condition pages connected to this study.